Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celgene’s Budding Blockbuster Abraxane Scoops Pancreatic Cancer Indication

This article was originally published in The Pink Sheet Daily

Executive Summary

Abraxane sales have been growing fast as Celgene has added new indications. Pancreatic cancer had been an off-label use prior to the new approval.

You may also be interested in...



Celgene Oncology Strategy: Seizing The Immuno-Hematology Opportunity

In back-to-back deals with AstraZeneca and Juno, Celgene has fronted nearly $1.5 billion to become a serious contender in the field of cancer immunotherapy, and is looking to lead in blood cancers.

Celgene Goes Big And Early: Aims For Two New Blockbusters And A Robust, Transformative Pipeline

The biotech has a three-pronged strategy to double revenues by 2017: continue to expand core multiple myeloma product Revlimid, bring new blockbusters online, and develop its early stage pipeline through deals.

Celgene’s Abraxane Scores A Win Against Tough Pancreatic Cancer

Abraxane more than doubled two-year survival and conferred a near-two-month overall survival advantage against pancreatic cancer compared with standard of care gemcitabine alone in the Phase III MPACT trial, presented Jan. 25 at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium in San Francisco. Celgene plans global regulatory filings by mid-2013.

Topics

Related Companies

UsernamePublicRestriction

Register

PS076340

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel